39 results on '"van Roon-Mom, Willeke M.C."'
Search Results
2. GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study
3. Early molecular layer interneuron hyperactivity triggers Purkinje neuron degeneration in SCA1
4. Generation of human induced pluripotent stem cell lines (LUMCi051-A,B and LUMCi052-A,B,C) of two patients with Spinocerebellar ataxia type 7
5. Generation of human induced pluripotent stem cell lines (LUMCi051-A,B and LUMCi052-A,B,C) of two patients with Spinocerebellar ataxia type 7
6. Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
7. Spinocerebellar Ataxia Type 1 Characteristics in Patient‐Derived Fibroblast and iPSC‐Derived Neuronal Cultures
8. Machine learning in Huntington’s disease:exploring the Enroll-HD dataset for prognosis and driving capability prediction
9. Spinocerebellar Ataxia Type 1 Characteristics in Patient-Derived Fibroblast and iPSC-Derived Neuronal Cultures
10. Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset
11. Antisense oligonucleotides in therapy for neurodegenerative disorders
12. Co-expression patterns of microglia markers Iba1, TMEM119 and P2RY12 in Alzheimer's disease
13. Iron accumulation induces oxidative stress, while depressing inflammatory polarization in human iPSC-derived microglia
14. Elevated brain iron is independent from atrophy in Huntington's Disease
15. Antisense Oligonucleotide-Induced Amyloid Precursor Protein Splicing Modulation as a Therapeutic Approach for Dutch-Type Cerebral Amyloid Angiopathy
16. Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension
17. Generation of a gene-corrected human isogenic line (UAMi006-A) from propionic acidemia patient iPSC with an homozygous mutation in the PCCB gene using CRISPR/Cas9 technology
18. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain
19. Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives.
20. CAG Repeat Size in the Normal HTT Allele and Age of Onset in Huntingtonʼs Disease
21. Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review.
22. Molecular investigation of TBP allele length:: a SCA17 cellular model and population study
23. Generation of genetically matched hiPSC lines from two mosaic facioscapulohumeral dystrophy type 1 patients
24. Generation of 5 induced pluripotent stem cell lines, LUMCi007-A and B and LUMCi008-A, B and C, from 2 patients with Huntington disease
25. Osteopontin and phospho‐SMAD2/3 are associated with calcification of vessels in D‐CAA, an hereditary cerebral amyloid angiopathy
26. Generation of 3 human induced pluripotent stem cell lines LUMCi005-A, B and C from a Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch type patient
27. Generation of 3 spinocerebellar ataxia type 1 (SCA1) patient-derived induced pluripotent stem cell lines LUMCi002-A, B, and C and 2 unaffected sibling control induced pluripotent stem cell lines LUMCi003-A and B
28. Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients
29. Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain
30. Co-expression Patterns between ATN1 and ATXN2 Coincide with Brain Regions Affected in Huntington’s Disease
31. Delivery is key:lessons learnt from developing splice-switching antisense therapies
32. Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
33. In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington’s disease
34. Preventing Formation of Toxic N-Terminal Huntingtin Fragments Through Antisense Oligonucleotide-Mediated Protein Modification
35. Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type
36. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon
37. Aggregate distribution in frontal and motor cortex in Huntington??s disease brain
38. TBP, a polyglutamine tract containing protein, accumulates in Alzheimer's disease
39. Insoluble TATA-binding protein accumulation in Huntington’s disease cortex
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.